Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Horne

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
International Journal of Cancer|February 24, 2018
Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue BankHannah Oh, Ruth M Pfeiffer, Roni T Falk, et al.
JCO Precision Oncology|September 11, 2020
Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology, US Food and Drug Administration Public Workshop-Workshop ProceedingsHisani N Horne, Donna Roscoe, E David Litwack, et al.
Breast Cancer Research and Treatment|December 3, 2013
Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expressionHisani N Horne, Mark E Sherman, Montserrat Garcia-Closas, et al.
Hormones & Cancer|May 4, 2016
Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast BiopsyHannah Oh, Zeina G Khodr, Mark E Sherman, et al.
Pharmacoepidemiology and Drug Safety|July 6, 2012
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studiesVincent Lo Re, Kevin Haynes, Eileen E Ming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation-Associated Advanced Ovarian CancerSanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, et al.
Breast Cancer Research : BCR|February 20, 2016
Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast diseaseHisani N Horne, Mark E Sherman, Ruth M Pfeiffer, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 10, 2015
Relationship of Terminal Duct Lobular Unit Involution of the Breast with Area and Volume Mammographic DensitiesGretchen L Gierach, Deesha A Patel, Ruth M Pfeiffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2018
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, et al.
Scientific Reports|April 28, 2018
E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association ConsortiumHisani N Horne, Hannah Oh, Mark E Sherman, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
International Journal of Cancer|February 24, 2018
Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue BankHannah Oh, Ruth M Pfeiffer, Roni T Falk, et al.
JCO Precision Oncology|September 11, 2020
Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology, US Food and Drug Administration Public Workshop-Workshop ProceedingsHisani N Horne, Donna Roscoe, E David Litwack, et al.
Breast Cancer Research and Treatment|December 3, 2013
Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expressionHisani N Horne, Mark E Sherman, Montserrat Garcia-Closas, et al.
Hormones & Cancer|May 4, 2016
Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast BiopsyHannah Oh, Zeina G Khodr, Mark E Sherman, et al.
Pharmacoepidemiology and Drug Safety|July 6, 2012
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studiesVincent Lo Re, Kevin Haynes, Eileen E Ming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation-Associated Advanced Ovarian CancerSanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, et al.
Breast Cancer Research : BCR|February 20, 2016
Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast diseaseHisani N Horne, Mark E Sherman, Ruth M Pfeiffer, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 10, 2015
Relationship of Terminal Duct Lobular Unit Involution of the Breast with Area and Volume Mammographic DensitiesGretchen L Gierach, Deesha A Patel, Ruth M Pfeiffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2018
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, et al.
Scientific Reports|April 28, 2018
E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association ConsortiumHisani N Horne, Hannah Oh, Mark E Sherman, et al.
Pageof 4